What did @elizabethsglp1journey actually say?
Elizabeth says she lost 40 pounds this year, 17 of them in 10 weeks after starting peptides in June. Her core argument is that peptides are misunderstood: they are "bio-identical to what your body already creates," they are not steroids, they are well-studied (she cites "over 80 FDA-approved peptides on the market"), and that muscle loss on GLP-1s is preventable. She also claims she personally takes GHK-Cu for "hair, skin, and nails" and NAD, and she lumps glutathione into the peptide category. She ends by directing followers to a podcast and to her pinned content, which raises its own questions about what she is actually promoting.
To her credit, she is trying to counter genuine misinformation. Some of what she says is grounded in real science. But several of her statistics are fuzzy, a few claims are misleading, and one substance she mentions is not a peptide at all.
Does the science back this up?
Partially. The claim that peptides are amino acid chains that the body naturally produces is accurate in principle, but "bio-identical" is doing a lot of heavy lifting here. The FDA-approved number is real but misleading in context. And the GLP-1 muscle loss point is supported by evidence, with caveats.
On the "7,000 peptides in your body" figure: research does support the existence of thousands of endogenous peptides. A 2014 review by Fricker et al. in the journal Bioscience Reports described the human peptidome as enormously complex, but the exact number is an estimate, not a fixed count. Saying your body has thousands of peptides does not mean synthetic lab-produced versions behave identically once injected or ingested.
The "80 FDA-approved peptides" figure appears to reference a count from industry and regulatory sources, and it is in the right ballpark. However, most of those approvals cover insulin analogs, hormone therapies, and oncology drugs, not the research peptides like BPC-157 or CJC-1295 that dominate the wellness peptide market. Conflating the two categories gives the impression that the entire class is vetted, when the specific peptides her audience is likely curious about are largely unstudied in humans.
On muscle loss: a 2024 study by Ida et al. in Diabetes, Obesity and Metabolism confirmed that GLP-1 receptor agonists are associated with lean mass loss alongside fat loss, but resistance training and adequate protein intake do meaningfully reduce that effect. Elizabeth is right on this one.
What did they get wrong (or right)?
The most straightforward error is calling NAD a peptide. It is not. NAD (nicotinamide adenine dinucleotide) is a coenzyme, a small molecule involved in cellular energy metabolism. It contains no amino acid chain. Grouping it with peptides is a factual mistake, not a gray area.
Similarly, glutathione is a tripeptide, so that one technically qualifies, but it is often taken orally where absorption is poor, or via IV in contexts that carry their own clinical considerations. Tossing it into a list without that context skips over something consumers should know.
The "bio-identical" framing for synthetic peptides is also slippery. GHK-Cu, for example, does occur naturally in human plasma, and research by Pickart and Margolina (2018, Cosmetics) supports its role in wound healing and skin remodeling. But "bio-identical" implies a seamless equivalency that glosses over differences in delivery method, concentration, and purity standards between pharmaceutical-grade and compounded or gray-market versions.
Where she deserves credit: correctly stating that peptides are not steroids, that muscle loss is not inevitable on GLP-1s, and that the peptide category extends well beyond weight loss are all accurate and useful corrections to common misconceptions.
What should you actually know?
The peptide category is not monolithic, and that is the core issue with videos like this one. Some peptides are rigorously studied and FDA-approved for specific indications. Others, including BPC-157 and TB-500, have compelling animal data but almost no controlled human trials. Treating them as equivalent because they share a molecular structure is like saying all drugs are safe because they share the category of "chemical compound."
Elizabeth lost real weight and her enthusiasm is genuine. But her 17-pounds-in-10-weeks result likely reflects tirzepatide or semaglutide, which are regulated, approved GLP-1 medications, not the research peptides she spends most of the video defending. Conflating her results with the broader peptide category, including unregulated research compounds, is where the video becomes potentially misleading for viewers who do not already know the difference.
If you are considering any peptide therapy, the specific compound matters enormously. Ask your provider which peptides have human clinical trial data, what the compounding pharmacy's quality certifications are, and whether the intended use has regulatory support. A podcast recommendation, however life-changing for the person sharing it, is not a substitute for that conversation.